Evidence map›Paper›PMID 32711552›Full record

ArticleDiagnostic pathology2020

The decisive role of molecular pathology in presumed somatic metastases of type II testicular germ cell tumors: report of 2 cases.

Mariëtte E G Kranendonk, Wenzel M Hackeng, G Johan A Offerhaus, Folkert H M Morsink, Geertruida N Jonges, Gerard Groenewegen, Pieter-Jaap Krijtenburg, Heinz-Josef Klümpen, Wendy W J de Leng, Leendert H J Looijenga and 1 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Diagnostic pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Primary hepatic mixed germ cell tumor in an adult.Journal of pathology and translational medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Mariëtte E G KranendonkDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0001-9683-7494
Wenzel M HackengDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
G Johan A OfferhausDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Folkert H M MorsinkDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Geertruida N JongesDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Gerard GroenewegenDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Pieter-Jaap KrijtenburgDepartment of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
Heinz-Josef KlümpenDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Wendy W J de LengDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Leendert H J LooijengaPrincess Máxima Center for Pedriatric Oncology, Utrecht, The Netherlands.
Lodewijk A A BrosensDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. L.A.A.Brosens@umcutrecht.nl.
University Medical Center Utrecht · NLAmsterdam University Medical Centers · NLPrincess Máxima Center · NLUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMolecular diagnostics can be decisive in the differential diagnosis between a somatic metastasis of type II testicular germ cell tumor (TGCT) or a second primary carcinoma. This is in line with recent recommendations from the International Society of Urological Pathology, based on an international survey which showed that molecular testing is currently only performed by a minority of urological pathologists. CASE PRESENTATIONS: This case report illustrates the necessity of molecular testing in two patients with a history of type II TGCT and a metastatic (retro) peritoneal carcinoma years later. The genetic hallmark of type II TGCT, chromosome 12p gain, was studied by fluorescence in situ hybridization and whole genome methylation profiling in case 1, and by single nucleotide polymorphism (SNP)-array in case 2. Next generation sequencing (NGS) was used to further explore clonality between the primary TGCT and peritoneal metastasis in case 2. In case 1, chromosome 12p gain was found in the primary type II TGCT and in the acinar cell carcinoma of the metastatic malignancy. In case 2, SNP array showed 12p gain in the epithelial component of the primary teratomatous TGCT but not in the peritoneal adenocarcinoma. Furthermore, NGS showed no mutations in the primary teratomatous TGCT but a KRAS and GNAS mutation in the peritoneal adenocarcinoma, suggestive of an appendicular origin.

conclusionsWithout the molecular data, both cases would have been regarded as a metastatic TGCT with development of somatic-type malignancy, which appeared a wrong diagnosis for case 2. These cases demonstrate the importance of molecular methods as an adjunct in today's pathology practice.

Indexed as

Pathology, MolecularChromosome AberrationsHumansIn Situ Hybridization, FluorescenceMaleNeoplasm MetastasisNeoplasms, Germ Cell and EmbryonalTeratomaTesticular NeoplasmsCase reportGain 12pMetastasisMolecular diagnosticsTesticular germ cell tumor

Identifiers

PMID32711552
PMCPMC7382836
OpenAlexW3044897815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.